Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 3.96% | |
50 DMA Resistance | Bearish | 1.44% | |
Gapped Up | Strength | 1.44% | |
200 DMA Resistance | Bearish | -0.48% | |
50 DMA Resistance | Bearish | -0.48% | |
Pocket Pivot | Bullish Swing Setup | -0.48% | |
Gapped Up | Strength | -0.48% | |
Upper Bollinger Band Touch | Strength | -0.48% | |
50 DMA Resistance | Bearish | 0.47% | |
Crossed Above 20 DMA | Bullish | 0.47% |
Alert | Time |
---|---|
10 DMA Support | 18 minutes ago |
20 DMA Support | about 1 hour ago |
Gap Up Closed | about 1 hour ago |
60 Minute Opening Range Breakdown | about 1 hour ago |
20 DMA Resistance | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Inflammatory Diseases Rheumatoid Arthritis Psoriasis Carcinoma Glaucoma Arthritis Hepatocellular Carcinoma Uveitis Immunosuppressants Biotie Therapies Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Treatment Of Psoriasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Inflammatory Diseases Rheumatoid Arthritis Psoriasis Carcinoma Glaucoma Arthritis Hepatocellular Carcinoma Uveitis Immunosuppressants Biotie Therapies Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Treatment Of Psoriasis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.33 |
52 Week Low | 1.81 |
Average Volume | 17,258 |
200-Day Moving Average | 2.27 |
50-Day Moving Average | 2.14 |
20-Day Moving Average | 2.03 |
10-Day Moving Average | 2.04 |
Average True Range | 0.15 |
RSI (14) | 45.05 |
ADX | 23.52 |
+DI | 26.00 |
-DI | 13.69 |
Chandelier Exit (Long, 3 ATRs) | 2.06 |
Chandelier Exit (Short, 3 ATRs) | 2.35 |
Upper Bollinger Bands | 2.20 |
Lower Bollinger Band | 1.87 |
Percent B (%b) | 0.46 |
BandWidth | 15.95 |
MACD Line | -0.03 |
MACD Signal Line | -0.04 |
MACD Histogram | 0.0105 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.20 | ||||
Resistance 3 (R3) | 2.22 | 2.18 | 2.17 | ||
Resistance 2 (R2) | 2.18 | 2.13 | 2.17 | 2.16 | |
Resistance 1 (R1) | 2.10 | 2.11 | 2.08 | 2.08 | 2.15 |
Pivot Point | 2.06 | 2.06 | 2.05 | 2.05 | 2.06 |
Support 1 (S1) | 1.98 | 2.01 | 1.96 | 1.96 | 1.89 |
Support 2 (S2) | 1.94 | 1.99 | 1.93 | 1.88 | |
Support 3 (S3) | 1.86 | 1.94 | 1.87 | ||
Support 4 (S4) | 1.84 |